Hidradenitis Suppurativa
📧 Sign up to get email alerts when something new happens for Hidradenitis Suppurativa.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-08-27EMA Authorised: Hulio (adalimumab) — Biosimilar Collaborations Ireland Limited
EMA authorised Hulio (adalimumab) biosimilar with approvals across multiple inflammatory indications.
-
EMA approval · 2026-08-24EMA Authorised: Yuflyma (adalimumab) — Celltrion Healthcare Hungary Kft.
EMA authorised Yuflyma (adalimumab) for multiple inflammatory diseases including rheumatoid arthritis and Crohn's disease.
-
CLINICAL_TRIALS trial_result · 2026-08-21Clinical Trial Update: A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa [Phase 3]
A Phase 3 trial evaluating long-term treatment with bimekizumab in adults with moderate to severe hidradenitis suppurativa has completed.
-
CLINICAL_TRIALS trial_result · 2026-08-12Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa [Phase 3]
Phase 3 trial evaluating subcutaneous sonelokimab versus placebo in adults with moderate to severe hidradenitis suppurativa has been complet…
-
EMA approval · 2026-08-06EMA Authorised: Idacio (adalimumab) — Fresenius Kabi Deutschland GmbH
European Medicines Agency authorises Idacio (adalimumab) from Fresenius Kabi Deutschland for multiple inflammatory diseases including rheuma…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-07-31Clinical Trial Update: A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa [Phase 3]
Phase 3 long-term study evaluating bimekizumab in participants with moderate to severe hidradenitis suppurativa is currently active but not …
-
EMA approval · 2026-07-30EMA Authorised: Hulio (adalimumab) — Biosimilar Collaborations Ireland Limited
Biosimilar adalimumab (Hulio) has been authorised by EMA for multiple indications including hidradenitis suppurativa, psoriasis, uveitis, rh…
-
EMA approval · 2026-07-17EMA Authorised: Hukyndra (adalimumab) — Stada Arzneimittel AG
EU authorization of Hukyndra (adalimumab) by Stada Arzneimittel AG for multiple inflammatory diseases including rheumatoid arthritis and inf…
-
EMA approval · 2026-07-13EMA Authorised: Libmyris (adalimumab) — Stada Arzneimittel AG
Authorised status for Libmyris (adalimumab) by Stada Arzneimittel AG for multiple inflammatory and autoimmune diseases.
-
EMA approval · 2026-07-13EMA Authorised: Idacio (adalimumab) — Fresenius Kabi Deutschland GmbH
European Medicines Agency authorises Idacio (adalimumab) for multiple inflammatory diseases, expanding the portfolio under Fresenius Kabi De…
-
CLINICAL_TRIALS trial_result · 2026-06-22Clinical Trial Update: A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa [Phase 3]
Phase 3 clinical trial update for long-term use of bimekizumab in moderate to severe hidradenitis suppurativa.
-
CLINICAL_TRIALS trial_result · 2026-06-17Clinical Trial Results: A Study to Test Long-term Treatment With Spesolimab in People With a Skin Condition Disease Called Hidradenitis Suppurativa (HS) Who Took Part in a Previous Study With Spesolimab [Phase 2, Phase 3]
Phase 2/3 trial evaluating long-term treatment with spesolimab in hidradenitis suppurativa (HS); the study has been terminated with results …
-
CLINICAL_TRIALS trial_result · 2026-06-08Clinical Trial Update: Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa [Phase 3]
Phase 3 trial evaluating subcutaneous sonelokimab vs placebo in adults with moderate to severe hidradenitis suppurativa has completed.
-
CLINICAL_TRIALS trial_result · 2026-06-08Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa [Phase 3]
Phase 3 trial evaluating subcutaneous sonelokimab vs placebo in adults with moderate to severe hidradenitis suppurativa has been completed.
-
EMA approval · 2026-06-05EMA Authorised: Idacio (adalimumab) — Fresenius Kabi Deutschland GmbH
The EMA has authorised Idacio (adalimumab) by Fresenius Kabi Deutschland GmbH for multiple inflammatory diseases, marking a new approved pro…
-
CLINICAL_TRIALS trial_result · 2026-06-05Clinical Trial Update: A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa [Phase 3]
A Phase 3 study evaluating the efficacy, safety, and tolerability of remibrutinib in adults and adolescents with moderate to severe hidraden…
-
CLINICAL_TRIALS trial_result · 2026-06-05Clinical Trial Update: A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa [Phase 3]
A Phase 3 long-term study evaluating bimekizumab in participants with moderate to severe hidradenitis suppurativa is active but not recruiti…
-
CLINICAL_TRIALS trial_result · 2026-06-03Clinical Trial Update: A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa [Phase 3]
Phase 3 clinical trial evaluating the efficacy and safety of lutikizumab in adults and adolescents with moderate to severe hidradenitis supp…
-
CLINICAL_TRIALS trial_result · 2026-04-28Clinical Trial Results: Topical Ruxolitinib 1.5% for Hidradenitis Suppurativa Treatment [Phase 2]
Phase 2 trial results for topical ruxolitinib 1.5% in hidradenitis suppurativa have been terminated with results posted.
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa [Phase 3]
An ongoing Phase 3 study evaluating long-term treatment with bimekizumab in adults with moderate to severe hidradenitis suppurativa; the stu…
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa [Phase 2]
This clinical trial update describes a Phase 2 study evaluating the efficacy and safety of SAR445399 in adults with moderate to severe hidra…
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: A Proof-of-Concept Study of LAD328 in Adults With Hidradenitis Suppurativa [Phase 2]
A Phase 2 proof-of-concept clinical trial of LAD328 in adults with hidradenitis suppurativa has been announced, with recruitment not yet sta…
-
CLINICAL_TRIALS trial_result · 2026-04-23Clinical Trial Update: Aviclear for Hidradenitis Suppurativa (HS) [NA]
Aviclear for hidradenitis suppurativa is listed as an active but not recruiting clinical trial, sponsored by the University of Miami.
-
CLINICAL_TRIALS trial_result · 2026-04-21Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients With Moderate to Severe Hidradenitis Suppurativa [Phase 2]
Phase 2 trial evaluating the efficacy and safety of AVTX-009 in moderate to severe hidradenitis suppurativa has completed.
-
CLINICAL_TRIALS research · 2026-04-21Clinical Trial Update: Long Term Observational Study to Collect in a Real-world populatIon Data on the Treatment Pattern of Secukinumab in Adult Patients With Moderate to Severe HS Within the Italian Population
This is a long-term observational study in Italy to collect real-world data on how Secukinumab is used to treat hidradenitis suppurativa in …